<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: There has been long-standing debate about whether <z:mp ids='MP_0002055'>diabetes</z:mp> is a causal risk factor for <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> or a consequence of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> development </plain></SENT>
<SENT sid="1" pm="."><plain>Prospective epidemiological studies have shown variable relationships between <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> risk and blood markers of <z:chebi fb="105" ids="17234">glucose</z:chebi> and insulin metabolism, overall and as a function of lag times between marker measurements (blood donation) and date of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> diagnosis </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Pre-diagnostic levels of HbA(1c) and C-<z:chebi fb="7" ids="16670">peptide</z:chebi> were measured for 466 participants with <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> and 466 individually matched controls within the European Prospective Investigation into <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> and Nutrition </plain></SENT>
<SENT sid="3" pm="."><plain>Conditional logistic regression models were used to estimate ORs for <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:hpo ids='HP_0002894'>Pancreatic cancer</z:hpo> risk gradually increased with increasing pre-diagnostic HbA(1c) levels up to an OR of 2.42 (95% CI 1.33, 4.39 highest [≥ 6.5%, 48 mmol/mol] vs lowest [≤ 5.4%, 36 mmol/mol] category), even for individuals with HbA(1c) levels within the non-diabetic range </plain></SENT>
<SENT sid="5" pm="."><plain>C-<z:chebi fb="7" ids="16670">peptide</z:chebi> levels showed no significant relationship with <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> risk, irrespective of fasting status </plain></SENT>
<SENT sid="6" pm="."><plain>Analyses showed no clear trends towards increasing <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> (as marked by HbA(1c) levels) or reduced pancreatic beta cell responsiveness (as marked by C-<z:chebi fb="7" ids="16670">peptide</z:chebi> levels) with decreasing time intervals from blood donation to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diagnosis </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS/INTERPRETATION: Our data on HbA(1c) show that individuals who develop exocrine <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> tend to have moderate increases in HbA(1c) levels, relatively independently of <z:hpo ids='HP_0001513'>obesity</z:hpo> and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>-the classic and major risk factors for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>While there is no strong difference by lag time, more data are needed on this in order to reach a firm conclusion </plain></SENT>
</text></document>